JP2018520653A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520653A5 JP2018520653A5 JP2017560907A JP2017560907A JP2018520653A5 JP 2018520653 A5 JP2018520653 A5 JP 2018520653A5 JP 2017560907 A JP2017560907 A JP 2017560907A JP 2017560907 A JP2017560907 A JP 2017560907A JP 2018520653 A5 JP2018520653 A5 JP 2018520653A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- cell
- variant
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 56
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 238000000034 method Methods 0.000 claims 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 210000001519 tissue Anatomy 0.000 claims 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 11
- 239000013604 expression vector Substances 0.000 claims 11
- 108091008874 T cell receptors Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 230000005847 immunogenicity Effects 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 238000010195 expression analysis Methods 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 108010028930 invariant chain Proteins 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000002493 microarray Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 238000003860 storage Methods 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000011502 immune monitoring Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940038309 personalized vaccine Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 238000012070 whole genome sequencing analysis Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562184500P | 2015-06-25 | 2015-06-25 | |
| GB1511191.7 | 2015-06-25 | ||
| US62/184,500 | 2015-06-25 | ||
| GBGB1511191.7A GB201511191D0 (en) | 2015-06-25 | 2015-06-25 | T-cell epitopes for the immunotherapy of myeloma |
| PCT/EP2016/064317 WO2016207164A2 (en) | 2015-06-25 | 2016-06-21 | Novel cell epitopes and combination of cell epitopes for use in the immuno-therapy of myeloma and other cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520653A JP2018520653A (ja) | 2018-08-02 |
| JP2018520653A5 true JP2018520653A5 (enExample) | 2019-06-27 |
Family
ID=53872214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560907A Pending JP2018520653A (ja) | 2015-06-25 | 2016-06-21 | 骨髄腫およびその他のがんの免疫療法において使用するための新規細胞エピトープおよび細胞エピトープ組み合わせ |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10196422B2 (enExample) |
| EP (1) | EP3313860A2 (enExample) |
| JP (1) | JP2018520653A (enExample) |
| KR (1) | KR20180012865A (enExample) |
| CN (1) | CN107889489A (enExample) |
| AU (1) | AU2016284857A1 (enExample) |
| BR (1) | BR112017027639A2 (enExample) |
| CA (1) | CA2990507A1 (enExample) |
| CR (1) | CR20180051A (enExample) |
| EA (1) | EA201792484A1 (enExample) |
| GB (1) | GB201511191D0 (enExample) |
| IL (1) | IL255932A (enExample) |
| MA (5) | MA41521A1 (enExample) |
| MX (1) | MX2017016207A (enExample) |
| PE (1) | PE20180174A1 (enExample) |
| SG (1) | SG10202001488VA (enExample) |
| TW (1) | TW201710289A (enExample) |
| WO (1) | WO2016207164A2 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| NZ721908A (en) | 2013-12-20 | 2022-12-23 | Massachusetts Gen Hospital | Combination therapy with neoantigen vaccine |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| EP4636401A2 (en) | 2014-12-19 | 2025-10-22 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
| EP3362929B1 (en) * | 2015-10-12 | 2020-08-12 | Nantomics, LLC | Viral neoepitopes and uses thereof |
| SG10202104041PA (en) | 2015-10-23 | 2021-06-29 | Harvard College | Nucleobase editors and uses thereof |
| KR102883915B1 (ko) | 2015-12-16 | 2025-11-18 | 시애틀 프로젝트 코포레이션 | 신생항원 동정, 제조, 및 용도 |
| JP2019511903A (ja) | 2016-02-19 | 2019-05-09 | ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ | 免疫原性調節の方法 |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| WO2018026914A1 (en) * | 2016-08-02 | 2018-02-08 | Nantcell, Inc. | Transfection of dendritic cells and methods therefor |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP3592381A1 (en) * | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| BR112019021094A2 (pt) | 2017-04-10 | 2020-05-12 | Immatics Biotechnologies Gmbh | Peptídeos e combinações dos mesmos para uso na imunoterapia contra leucemias e outros cânceres |
| WO2018189152A2 (en) * | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| WO2018224166A1 (en) * | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| PT3428194T (pt) | 2017-07-14 | 2021-11-18 | Immatics Biotechnologies Gmbh | Molécula de polipéptido com especificidade dupla melhorada |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| KR20260008173A (ko) | 2017-11-22 | 2026-01-15 | 시애틀 프로젝트 코포레이션 | 신생항원에 대한 접합 에피토프 제시 감소 |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| CN107937515B (zh) * | 2017-12-06 | 2018-11-09 | 北京泱深生物信息技术有限公司 | 一种阿尔茨海默的诊疗基因靶点及其应用 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| JP7470640B2 (ja) | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| WO2020047138A1 (en) * | 2018-08-29 | 2020-03-05 | Amyris, Inc. | Cells and methods for selection based assay |
| US11702450B2 (en) * | 2018-08-30 | 2023-07-18 | Université de Montréal | Proteogenomic-based method for identifying tumor-specific antigens |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| EP3942043A2 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| MA56036A (fr) | 2019-05-27 | 2022-04-06 | Immatics Us Inc | Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive |
| US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| MX2022000046A (es) * | 2019-06-25 | 2022-02-24 | Univ Montreal | Novedosos antigenos especificos de tumores para cancer de ovario y usos de estos. |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021101965A1 (en) * | 2019-11-18 | 2021-05-27 | Epivax Oncology, Inc. | Improved neo-epitope vaccines and methods of treating cancer |
| TW202144389A (zh) * | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| IL296714A (en) * | 2020-03-27 | 2022-11-01 | Univ Indiana Trustees | Immunotherapeutic targets in multiple myeloma and methods for their detection |
| BR112022022603A2 (pt) | 2020-05-08 | 2023-01-17 | Broad Inst Inc | Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla |
| KR102361479B1 (ko) * | 2020-06-18 | 2022-02-11 | 고려대학교 산학협력단 | ｓｉＲＮＡ의 생성 및 기능 증진 활성을 갖는 ＣＭＴＲ１의 신규용도 |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| WO2022086727A1 (en) * | 2020-10-19 | 2022-04-28 | Nantbio, Inc. | Arrayed peptide neoepitope generator |
| PE20250846A1 (es) | 2020-12-31 | 2025-03-21 | Immatics Us Inc | Polipeptidos cd8, composiciones y metodos de uso de estos |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| CN113476619B (zh) * | 2021-07-08 | 2022-11-29 | 上海交通大学医学院附属仁济医院 | 一种18f标记纳米抗体探针及其制备方法和应用 |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| EP4408468A4 (en) | 2021-09-28 | 2025-07-02 | Frontaim Biomedicines Inc | MULTIPLE FORMATS OF MOLECULAR COMPLEXES |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2026096743A1 (en) | 2024-10-30 | 2026-05-07 | Immatics US, Inc. | Methods for gamma delta t cells manufacturing |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7368531B2 (en) * | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| WO2003064599A2 (en) * | 2002-01-25 | 2003-08-07 | Origene Technologies, Inc | Cancer genes |
| JP4472351B2 (ja) * | 2002-03-01 | 2010-06-02 | イミューノメディクス、インコーポレイテッド | インターナライジング抗ｃｄ７４抗体およびその使用方法 |
| DE10360456A1 (de) * | 2003-12-22 | 2005-07-28 | Vaecgene Biotech Gmbh | Tumorantigene und deren Verwendung |
| JP5109131B2 (ja) * | 2005-02-10 | 2012-12-26 | オンコセラピー・サイエンス株式会社 | 膀胱癌を診断する方法 |
| EP1760089B1 (en) | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| WO2008009004A2 (en) * | 2006-07-13 | 2008-01-17 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in signaling pathways |
| BRPI0813626A2 (pt) * | 2007-07-27 | 2014-12-23 | Immatics Biotechnologies Gmbh | Epitopos imunogênicos para a imunoterapia |
| BRPI0814140A2 (pt) * | 2007-07-27 | 2017-03-28 | Immatics Biotechnologies Gmbh | composição de peptídeos associados a tumor e vacina anticâncer relacionada |
| US20100209427A1 (en) * | 2008-09-24 | 2010-08-19 | Yu Li | Lysine acetylation sites |
| WO2011119484A1 (en) * | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| EP2925348B1 (en) * | 2012-11-28 | 2019-03-06 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
| CA2902841A1 (en) * | 2013-03-13 | 2014-10-02 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| WO2014200910A2 (en) * | 2013-06-10 | 2014-12-18 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
-
2015
- 2015-06-25 GB GBGB1511191.7A patent/GB201511191D0/en not_active Ceased
-
2016
- 2016-06-16 TW TW105118858A patent/TW201710289A/zh unknown
- 2016-06-21 BR BR112017027639-9A patent/BR112017027639A2/en not_active Application Discontinuation
- 2016-06-21 MA MA41521A patent/MA41521A1/fr unknown
- 2016-06-21 AU AU2016284857A patent/AU2016284857A1/en not_active Abandoned
- 2016-06-21 MA MA46504A patent/MA46504A1/fr unknown
- 2016-06-21 CN CN201680037125.9A patent/CN107889489A/zh active Pending
- 2016-06-21 PE PE2017002495A patent/PE20180174A1/es unknown
- 2016-06-21 MA MA46508A patent/MA46508A1/fr unknown
- 2016-06-21 MX MX2017016207A patent/MX2017016207A/es unknown
- 2016-06-21 CA CA2990507A patent/CA2990507A1/en not_active Abandoned
- 2016-06-21 EP EP16732263.5A patent/EP3313860A2/en not_active Withdrawn
- 2016-06-21 MA MA46507A patent/MA46507A1/fr unknown
- 2016-06-21 WO PCT/EP2016/064317 patent/WO2016207164A2/en not_active Ceased
- 2016-06-21 CR CR20180051A patent/CR20180051A/es unknown
- 2016-06-21 KR KR1020187001628A patent/KR20180012865A/ko not_active Withdrawn
- 2016-06-21 EA EA201792484A patent/EA201792484A1/ru unknown
- 2016-06-21 MA MA46506A patent/MA46506A1/fr unknown
- 2016-06-21 JP JP2017560907A patent/JP2018520653A/ja active Pending
- 2016-06-21 SG SG10202001488VA patent/SG10202001488VA/en unknown
- 2016-06-24 US US15/191,895 patent/US10196422B2/en active Active
-
2017
- 2017-11-26 IL IL255932A patent/IL255932A/en unknown
-
2018
- 2018-11-20 US US16/196,812 patent/US10377797B2/en active Active